You are here

Combo Diabetes Treatment Soliqua Wins FDA Nod

Product will be available in January

The FDA has approved once-daily Soliqua 100/33 (Sanofi), a combination of Lantus (insulin glargine 100 U/mL) and the glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (33 mcg/mL), for the treatment of adults with type-2 diabetes (T2D) inadequately controlled with basal insulin (less than 60 units daily) or lixisenatide alone.

In an insulin-intensification study, the American Diabetes Association target of a hemoglobin A1c level below 7% at 30 weeks was achieved by 55% of patients treated with Soliqua 100/33 compared with 30% of those treated with insulin glargine (Lantus) alone. The two treatment groups showed similar rates of hypoglycemia (less than or equal to 70 mg/dL). The most frequently reported adverse events included hypoglycemia as well as nausea (10%), nasopharyngitis (7%), diarrhea (7%), and upper respiratory tract infection (5%).

Soliqua 100/33 will be delivered in a single prefilled pen for once-daily dosing covering 15 to 60 units of insulin glargine 100 U/mL and five to 20 mcg of lixisenatide. The product will be available in U.S. retail pharmacies in January 2017.

Soliqua 100/33 has not been studied in people with a history of pancreatitis. It is not recommended for people who also take lixisenatide or other GLP-1 receptor agonists, nor is it for use in people with type-1 diabetes or diabetic ketoacidosis, or in those who have gastroparesis. Soliqua 100/33 has not been studied together with short-acting insulin. It is not known whether the product is safe and effective in children less than 18 years of age.

Sources: Sanofi; November 21, 2016; and Soliqua Prescribing Information; November 2016.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time